Your browser doesn't support javascript.
loading
Potential alternative treatment approach for pediatric patient with diffusely infiltrative primary rhabdomyosarcoma of the liver.
Patel, Rushil; Roberson, John; Prakash, Devina; Meyer, Rina; Hogan, Laura; Azmy, Christeen; Suprenant, Valmore; Ryu, Samuel; Stessin, Alexander.
Afiliação
  • Patel R; Renaissance School of Medicine, Stony Brook University, Stony Brook, NY, United States.
  • Roberson J; Department of Radiation Oncology, Stony Brook University Hospital, Stony Brook, NY, United States.
  • Prakash D; Division of Pediatric Hematology Oncology, Stony Brook Children's Hospital, Stony Brook, NY, United States.
  • Meyer R; Division of Pediatric Hematology Oncology, Stony Brook Children's Hospital, Stony Brook, NY, United States.
  • Hogan L; Division of Pediatric Hematology Oncology, Stony Brook Children's Hospital, Stony Brook, NY, United States.
  • Azmy C; Division of Pediatric Hematology Oncology, Stony Brook Children's Hospital, Stony Brook, NY, United States.
  • Suprenant V; Department of Radiology, Stony Brook University Hospital, Stony Brook, NY, United States.
  • Ryu S; Department of Radiation Oncology, Stony Brook University Hospital, Stony Brook, NY, United States.
  • Stessin A; Department of Radiation Oncology, Stony Brook University Hospital, Stony Brook, NY, United States.
Rep Pract Oncol Radiother ; 26(1): 143-148, 2021.
Article em En | MEDLINE | ID: mdl-34046225
ABSTRACT
Primary hepatic rhabdomyosarcoma is rare, making decisions regarding locoregional management with resection and/or conventional radiation difficult. We present a novel treatment approach for a pediatric patient diagnosed with rhabdomyosarcoma diffusely involving the liver. This patient underwent treatment with yttrium-90 (Y-90) microspheres followed by external beam radiation therapy (EBRT ) to residual disease, interdigitated with systemic chemotherapy. Initial post-radiation imaging showed significant response to treatment, and she experienced minimal acute toxicities and no long-term toxicities. She developed recurrent PET-avid disease 23 months after Y-90 treatment, necessitating further local and continued systemic therapies. We report on the tumor control following Y-90 and EBRT treatment.
Palavras-chave

Texto completo: 1 Base de dados: MEDLINE Idioma: En Ano de publicação: 2021 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Idioma: En Ano de publicação: 2021 Tipo de documento: Article